×
About 3,499 results

ALLMedicine™ Peritoneal Cancer Center

Research & Reviews  1,665 results

Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still sta...
https://doi.org/10.1016/j.ejso.2020.08.020
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology; Sgarbura O, Villeneuve L et. al.

Sep 9th, 2020 - PIPAC is a new treatment modality for peritoneal cancer which has been practiced and evaluated until very recently by few academic centers in a highly standardized manner. Encouraging oncological outcomes and the safety profile have led to widespr...

Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectab...
https://doi.org/10.1245/s10434-020-09064-7
Annals of Surgical Oncology; Berger Y, Schuitevoerder D et. al.

Sep 6th, 2020 - Peritoneal metastases (PMs) from appendiceal ex-goblet adenocarcinoma (AEGA) are associated with a poor prognosis. While cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to prolong survival, the maj...

Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer.
https://doi.org/10.21873/anticanres.14529
Anticancer Research; Madsen CV, Adimi P et. al.

Sep 3rd, 2020 - Treatment of recurrent platinum-resistant ovarian cancer remains challenging due to the development of resistance to chemotherapy. Cabazitaxel is a new taxane that has demonstrated beneficial effect in prostate cancer patients resistant to docetax...

Distribution Characteristics of Colorectal Peritoneal Carcinomatosis Based on the Posit...
https://doi.org/10.1089/cbr.2020.3733
Cancer Biotherapy & Radiopharmaceuticals; Sun CF, Tan ZH et. al.

Aug 24th, 2020 - Background: Colorectal peritoneal carcinomatosis (CRPC) is a primary cause of death in colorectal cancer (CRC) patients. In the past, computed tomography (CT) has been the primary method used to evaluate the distribution of CRPC. This study uses 1...

To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage I...
https://doi.org/10.1080/01443615.2020.1787967
Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology; Kumari A, Thakur M et. al.

Aug 18th, 2020 - This study aimed to compare the impact of 3 versus 6 cycles of neoadjuvant chemotherapy (NACT) on the optimal cytoreduction in patients of advanced ovarian malignancy during interval debulking surgery (IDS). Thirty patients with advanced-stage III...

see more →

Guidelines  19 results

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response ...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer...

BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1

Aug 20th, 2019 - The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations...

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer - US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2748515

Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is t...

Cancer incidence in the Agricultural Health Study after 20 years of follow-up
https://link.springer.com/article/10.1007%2Fs10552-019-01140-y
Cancer Causes & Control; Lerro,C.,et al

Feb 24th, 2019 - To evaluate cancer incidence in the Agricultural Health Study (AHS), a cohort of private pesticide applicators, their spouses, and commercial applicators, based on 12,420 cancers, adding 5,989 cancers, and 9 years of follow-up since last evaluatio...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  1,759 results

SGO 2020: Updated Data From PRIMA Trial: Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancer
https://ascopost.com/issues/september-10-2020-supplement-gynecologic-cancers-almanac/updated-data-from-prima-trial-niraparib-as-first-line-maintenance-therapy-for-advanced-ovarian-cancer/

Sep 9th, 2020 - Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three poly (ADP-ribose) polymerase (PARP) inhibitors at the European Society for Medical Oncology (ESMO) ...

Novel Drug Approvals and New Indications for Gynecologic Cancers
https://ascopost.com/issues/september-10-2020-supplement-gynecologic-cancers-almanac/novel-drug-approvals-and-new-indications-for-gynecologic-cancers/

Sep 9th, 2020 - A number of new drugs and novel indications were added to the treatment armamentarium for gynecologic cancers over the past year. The U.S. Food and Drug Administration (FDA) approvals are noted here. Olaparib, PARP Inhibitor On May 8, 2020, the FD...

Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): Still sta...
https://doi.org/10.1016/j.ejso.2020.08.020
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology; Sgarbura O, Villeneuve L et. al.

Sep 9th, 2020 - PIPAC is a new treatment modality for peritoneal cancer which has been practiced and evaluated until very recently by few academic centers in a highly standardized manner. Encouraging oncological outcomes and the safety profile have led to widespr...

Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectab...
https://doi.org/10.1245/s10434-020-09064-7
Annals of Surgical Oncology; Berger Y, Schuitevoerder D et. al.

Sep 6th, 2020 - Peritoneal metastases (PMs) from appendiceal ex-goblet adenocarcinoma (AEGA) are associated with a poor prognosis. While cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to prolong survival, the maj...

Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer.
https://doi.org/10.21873/anticanres.14529
Anticancer Research; Madsen CV, Adimi P et. al.

Sep 3rd, 2020 - Treatment of recurrent platinum-resistant ovarian cancer remains challenging due to the development of resistance to chemotherapy. Cabazitaxel is a new taxane that has demonstrated beneficial effect in prostate cancer patients resistant to docetax...

see more →

News  47 results

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response ...

Is it time to expand the use of PARP inhibitors?
https://www.mdedge.com/hematology-oncology/article/210908/genitourinary-cancer/it-time-expand-use-parp-inhibitors/page/0/1?channel=61051

Oct 25th, 2019 - Advanced ovarian cancer The randomized, double-blind, placebo-controlled, phase 3 PAOLA-1/ENGOT-ov25 trial studied patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer who had surgery, platinum-taxane chemotherapy, and.

GSK gets FDA nod for wider use of ovarian cancer drug Zejula
https://www.reuters.com/article/us-gsk-zejula-fda/gsk-gets-fda-nod-for-wider-use-of-ovarian-cancer-drug-zejula-idUSKBN1X22V5

Oct 23rd, 2019 - (Reuters) - GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker’s oncology portfolio as it competes with rival AstraZeneca. FILE PHOTO: T...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer...

see more →